Roman's ED Funded Longitudinal Care
Ro
Roman shows how Ro’s original business became infrastructure for the next one. ED was a strong early wedge because patients could fill out a quick intake, get a clinician review, and receive low cost generic sildenafil by mail, which created a dependable subscription base. But once generics spread and more telehealth brands copied the same playbook, price and ad spend became the main battleground, so Roman kept throwing off cash while faster growing GLP-1 care took over the mix.
-
Roman was the core engine for years. ED represented about 60% of Ro revenue in 2021, and the broader early D2C telehealth model worked by giving away the consult and making money on monthly generic drug fulfillment, with roughly 65% gross margins in the category.
-
The weakness in ED is structural, not cyclical. Viagra went generic in 2017, competitors like Hims entered the same market at the same time, many fast followers piled in, CAC rose, and yearly churn for Ro and peers reached about 50% at points because patients could switch among nearly identical offers with little friction.
-
Roman still matters because it taught Ro how to run repeatable medication workflows. The same intake, prescribing, fulfillment, and renewal loop that worked for ED became the base for more complex lines, but obesity care carries higher order values and recurring care fees, so each new Ro Body patient is worth much more than a legacy ED patient.
Going forward, Roman is likely to function less like the story and more like the funding source. The center of gravity is shifting from simple cash pay generics toward longitudinal care programs where Ro can justify higher revenue per patient through labs, monitoring, pharmacy coordination, and manufacturer ties, which is where the next margin pool and competitive moat will be built.